14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TKNO vs AYTU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Alpha Teknova, Inc. (TKNO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TKNO carries a Unified Composite Score of 37.6/100 (SELL) at $7.90 (N/M Forward P/E, -31.6% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).
Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. TKNO 37.6/100 SELL) and 0.65β · 35% Vol risk profile, whereas TKNO leads top-line expansion (+21.5% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: TKNO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.8); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TKNO vs AYTU. Trailing 12-month operating profitability (TKNO -31.6% vs AYTU -14.4%) and valuation multiples (TKNO N/M vs AYTU 9.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment78.4% of Rev ($45M)
90D Engineering Disclosures0 Published
Investor FAQ TKNO vs AYTU Key Questions & Quantitative Answers
As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over Alpha Teknova, Inc. (TKNO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TKNO carries a Unified Composite Score of 37.6/100 (SELL) at $7.90 (N/M Forward P/E, -31.6% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. TKNO 37.6/100 SELL) and 0.65β · 35% Vol risk profile, whereas TKNO leads top-line expansion (+21.5% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TKNO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 50.8); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TKNO leads the Growth & Scale pillar: TKNO posts +21.5% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (36.4% gross margin, -31.6% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). On trailing 12-month operating scale, TKNO generates $46M in USD-normalized revenue versus $58M for AYTU. In operating R&D and SG&A reinvestment, TKNO deploys 68.0% of Rev ($31M) (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.
AYTU screens cheaper on headline valuation multiples. TKNO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.4x EV/Revenue (-17.8% EBITDA margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TKNO (-24.1% ROE) versus AYTU (-52.5% ROE) capital efficiency.
In options market volatility and institutional positioning, TKNO carries 10.6% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 114% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.